NeuroSense Says Phase 2b ALS Study Meets Primary Endpoint

June 29, 2026 — 09:49 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - NeuroSense Therapeutics Ltd. (NRSN) on Monday said its Phase 2b PARADIGM study of PrimeC in patients with amyotrophic lateral sclerosis (ALS) met its primary efficacy endpoint, demonstrating a statistically significant reduction in TDP-43 levels compared with placebo.

The company said the trial is the first randomized, double-blind, placebo-controlled study to show a treatment-related reduction in TDP-43, a key pathological hallmark of ALS, in people living with the disease.

NeuroSense said the effect was sustained and deepened throughout the 18-month study, with patients receiving continuous PrimeC treatment maintaining lower TDP-43 levels than those in the placebo group at Day 540.

The company has received U.S. Food and Drug Administration clearance to begin its Phase 3 PARAGON study and is continuing regulatory discussions in multiple jurisdictions, including Canada.

NeuroSense Shares are currently trading at $0.8001, up 5.64%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

NeuroSense Says Phase 2b ALS Study Meets Primary Endpoint

Tags

Latest Articles